These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11217527)

  • 21. Pharmacotherapy in depressed children and adolescents.
    Taurines R; Gerlach M; Warnke A; Thome J; Wewetzer C
    World J Biol Psychiatry; 2011 Sep; 12 Suppl 1():11-5. PubMed ID: 21905988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation criteria for panic disorder as a nosological entity.
    Rosenberg R; Ottosson JO; Bech P; Mellergård M; Rosenberg NK
    Acta Psychiatr Scand Suppl; 1991; 365():7-17. PubMed ID: 1862735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lactate vulnerability after alprazolam versus placebo treatment of panic disorder.
    Cowley DS; Dager SR; Roy-Byrne PP; Avery DH; Dunner DL
    Biol Psychiatry; 1991 Jul; 30(1):49-56. PubMed ID: 1892962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can recovery from depression be achieved?
    Shelton RC; Tomarken AJ
    Psychiatr Serv; 2001 Nov; 52(11):1469-78. PubMed ID: 11684742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depression and anxiety: pharmacological treatment in general practice.
    Ellen S; Selzer R; Norman T; Blashki G
    Aust Fam Physician; 2007 Apr; 36(4):222-8. PubMed ID: 17392933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy.
    Olatunji BO; Feldman G; Smits JA; Christian KM; Zalta AK; Pollack MH; Simon NM
    Depress Anxiety; 2008; 25(2):167-71. PubMed ID: 17335002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder.
    Lydiard RB; Laraia MT; Ballenger JC; Howell EF
    Am J Psychiatry; 1987 May; 144(5):664-5. PubMed ID: 3578580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality-of-life impairment in depressive and anxiety disorders.
    Rapaport MH; Clary C; Fayyad R; Endicott J
    Am J Psychiatry; 2005 Jun; 162(6):1171-8. PubMed ID: 15930066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivors of torture presenting at an anxiety disorders clinic: symptomatology and pharmacotherapy.
    Bouwer C; Stein DJ
    J Nerv Ment Dis; 1998 May; 186(5):316-8. PubMed ID: 9612450
    [No Abstract]   [Full Text] [Related]  

  • 30. Mental health care in Japan: recognition and treatment of depression and anxiety disorders.
    Tajima O
    J Clin Psychiatry; 2001; 62 Suppl 13():39-44; discussion 45-6. PubMed ID: 11434417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment response and redefining diagnostic boundaries.
    Hollander E
    CNS Spectr; 2008 Dec; 13(12):1020-1. PubMed ID: 19179937
    [No Abstract]   [Full Text] [Related]  

  • 32. Prescription-event monitoring of 10,895 patients treated with alprazolam.
    Edwards JG; Inman WH; Pearce GL; Rawson NS
    Br J Psychiatry; 1991 Mar; 158():387-92. PubMed ID: 2036539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mood disorders].
    Passerieux C; Hardy-Baylé MC
    Rev Prat; 2008 Oct; 58(16):1809-14. PubMed ID: 19143154
    [No Abstract]   [Full Text] [Related]  

  • 34. The Treatment of Migraine Headache in the Presence of Selective Serotonin Reuptake Inhibitor Use: Pharmacokinetic Considerations.
    Macca AL
    J Neurosci Nurs; 2015 Aug; 47(4):235-8; quiz E1. PubMed ID: 26153788
    [No Abstract]   [Full Text] [Related]  

  • 35. The importance of new antidepressants in the treatment of anxiety/depressive disorders.
    Boerner RJ; Möller HJ
    Pharmacopsychiatry; 1999 Jul; 32(4):119-26. PubMed ID: 10505481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
    Cassano GB; Puca F; Scapicchio PL; Trabucchi M;
    J Clin Psychiatry; 2002 May; 63(5):396-402. PubMed ID: 12019663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Depression and anxiety. Broad spectrum SSRI to control both].
    MMW Fortschr Med; 2001 Sep; 143(35-36):55-6. PubMed ID: 11584534
    [No Abstract]   [Full Text] [Related]  

  • 40. [Sertraline in child and adolescent psychiatry].
    Voloshina VM; Kashnikova AA; Tatarova IN; Kim LV; Koren' EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):25-8. PubMed ID: 11552629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.